Holen Sie sich die Stockscreener-App
13.79
8.61%
1.135
Turn Therapeutics Inc Aktie (TTRX) Neueste Nachrichten
Turn Therapeutics Names Former CDC Director Robert Redfield Chief Scientific Officer - citybiz
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer - BioSpace
Turn Therapeutics Names Robert Redfield Chief Scientific Officer - TipRanks
Former CDC Director Robert Redfield Joins Turn Therapeutics as Chief Scientific Officer - Dermatology Times
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
TTRX - Finviz
Turn Therapeutics (NASDAQ:TTRX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Ieq Capital LLC Makes New Investment in Turn Therapeutics Inc. $TTRX - MarketBeat
Turn (TTRX) Levels: Records a 2.33% Increase to $9.68 in the Current Update; Levels: $9.20 and $10.16 Define the Nearby Reference Levels in the Latest SessionContinuation Pattern Picks - vinanet.vn
Turn (TTRX) Session: Records a 0.84% Decrease to $9.46 on the Day; Range Check: Traders Can Monitor the $8.99-$9.93 Range in the Available RecordFibonacci Entry Signals - vinanet.vn
Turn (TTRX) Results Breakdown: Available Metrics Are Broadly in Line for the Current Session; After Earnings: The Stock Ends Down 2.85% at the CloseGuidance Accuracy Score - vinanet.vn
Turn (TTRX) Close: Ends Lower by 0.20% at $9.80 on the Day; Current Setup: Traders Can Monitor the $9.31-$10.29 Range in Latest TradingWedge Breakout - vinanet.vn
GX-03 Selectively Reduces Key Drivers of Skin Inflammation, Itch - The Dermatology Digest
GX-03 Cuts Itch-Related Cytokine IL-31 by Nearly 68% in AD Model - Dermatology Times
Turn Therapeutics publishes study on GX-03 skin therapy - Investing.com
Turn Therapeutics publishes study on GX-03 skin therapy By Investing.com - Investing.com Canada
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch - Business Wire
Turn Therapeutics Issues 579,664 Shares in Cashless Warrant Exercise - Minichart
Form 8K Turn Therapeutics Inc For: 18 August By Investing.com - Investing.com South Africa
Turn Therapeutics Reports Unregistered Cashless Warrant Share Issuance - TipRanks
Turn Therapeutics Completes Cashless Exercise of GEM Warrant, Issues 579,664 Shares - Kalkine Media
Turn Therapeutics Raises $1.35 Million in Private Placement - Minichart
Turn Therapeutics Secures $1.35 Million Through Private Stock Placement - Kalkine Media
Turn Therapeutics Raises $1.35M Through Private Placement - TipRanks
Turn Therapeutics (TTRX) Rallies 3.55% to $9.91, Approaching Key $10.41 ResistanceBeta Neutral Pair - vinanet.vn
Ladenburg Thalmann Initiates Turn Therapeutics(TTRX.US) With Buy Rating, Announces Target Price $16 - Moomoo
Turn Therapeutics (NASDAQ:TTRX) Stock Price Down 6.5%Time to Sell? - MarketBeat
Turn Therapeutics Inc. announced that it expects to receive $1.35 million in funding - marketscreener.com
Turn Therapeutics (TTRX) Falls 5.6% to $9.95 as Support at $9.45 Comes into FocusRetracement Entry - vinanet.vn
Turn Therapeutics Announces Q2 2026 Financial Results with Increased Net Loss and Long-Term Debt - Kalkine Media
Form 8K Turn Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Turn Therapeutics (NASDAQ: TTRX) posts larger loss, adds debt and warns on going concern - Stock Titan
Turn Therapeutics Q2 net loss per share widens on higher R&D costs - TradingView
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Turn Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Turn Therapeutics Rings the Closing Bell - Nasdaq
Turn Therapeutics Ord Shs (TTRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Price to sales forward of Turn Therapeutics Inc. – NASDAQ:TTRX - TradingView
Turn Therapeutics (TTRX) Advances 3.82% to $8.56 as Biotech Buying Interest IntensifiesValue ETF - vinanet.vn
Turn Therapeutics Inc. Revenue Breakdown – NASDAQ:TTRX - TradingView
Turn Therapeutics Updates GX-03 Investor Presentation and Pipeline - TipRanks
Turn updates investor presentation, cites Q4 2026 AD Phase 2 topline and $11.2M cash - TradingView
GX-03 trial data and cash runway at Turn Therapeutics (NASDAQ: TTRX) - Stock Titan
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026 - Business Wire
Turn Therapeutics Ord Shs (TTRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TTRX|Turn Therapeutics Ord Shs|Price:9.575|Chg%:+0.735 - TradingKey
Turn Therapeutics (TTRX) Plunges Nearly 10% as Stock Approaches Key Support ZoneFactor Momentum - vinanet.vn
TTRX Forecast — Price Target — Prediction for 2027 - TradingView
Turn Therapeutics Inc. Common Stock (NASDAQ: TTRX) Stock Price, News & Analysis - Kalkine
Zacks Research Upgrades Turn Therapeutics (NASDAQ:TTRX) to Hold - MarketBeat
Enterprise value to revenue forward of Turn Therapeutics Inc. – NASDAQ:TTRX - TradingView
Subscribers: Disregard Turn Therapeutics Shares Rise Article - Moomoo
LADENBURG THALM/SH SH Upgrades Turn Therapeutics (NASDAQ:TTRX) to Strong-Buy - MarketBeat
Turn Therapeutics Shares Rise on Expanded Phase 2 Study For Eczema Treatment - Moomoo
Ladenburg Thalmann Initiates Turn Therapeutics at Buy With $26 Price Target - Moomoo
TTRX Q1 2026 Earnings: Narrow EPS Miss Amid Positive Stock ReactionCash Flow Report - vinanet.vn
Why is Turn Therapeutics stock trading higher today? - MSN
0.28%
4.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):